MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Breakthrough In Eye Cancer Treatment

Back to ophthalmology news Blogs list Cancer blog  


Subscribe To Ophthalmology News RSS Feed  RSS content feed What is RSS feed?

Breakthrough In Eye Cancer Treatment

Breakthrough In Eye Cancer Treatment
Researchers at St. Jude Children's Research Hospital have demonstrated in a mouse model a new, locally applied therapy for the eye cancer retinoblastoma that not only greatly reduces the size of the tumor, but does so without causing the side effects common with standard chemotherapy. The therapy also appears to be suitable for certain forms of breast, lung, prostate and colon cancer, and is simple enough for widespread use even in countries with limited resources.

A report on this work appears in the Nov. 2 issue of the journal Nature.

Retinoblastoma occurs in about 5,000 young children worldwide each year, arising from the immature retina, which is the part of the eye responsible for detecting light and color. The cancer is fatal if left untreated.

The new therapy holds promise for a simpler, more effective and less-toxic therapy for retinoblastoma that would eliminate the need for the current, complex treatment, as per senior author Michael Dyer, Ph.D., a Pew Scholar and associate member of the St. Jude Department of Developmental Neurobiology. The therapy is based on a discovery by Dyer's laboratory that overturned a widely held belief about the process of apoptosis (cell suicide) in retinoblastoma. Apoptosis is the way the body rids itself of abnormal cells that might become malignant or cause other problems.

Until now, retinoblastoma experts thought that a mechanism called the p53 pathway triggered apoptosis in other types of cancer cells, but not in retinoblastoma. However, the St. Jude team proved not only that the p53 pathway was activated in early-stage retinoblastoma, but that excessive levels of a molecule called MDMX blocked it from triggering apoptosis in more advanced tumors. Based on this discovery, the St. Jude team used a molecule called nutlin-3 to block MDMX in retinoblastoma cells in test tube studies as well as in mouse models. The molecule was originally developed by.

Roche Pharmaceuticals (Nutley, N.J.) for a similar use against a related target called MDM2 in adult cancer cells.

The success in knocking out MDMX with nutlin-3 represents the first example of local delivery of a targeted chemotherapy drug for any childhood cancer, Dyer said.

Targeted treatment uses a customized drug to disable a specific molecule inside a growing cancer cell; local delivery is the placement of a drug at the site of disease, rather than systemic therapy. In systemic therapy, such as chemotherapy, a drug is infused into the body through a vein and then circulates, often causing toxic side effects that are particularly challenging in children.

After demonstrating that nutlin-3 is effective when applied directly to the eye, the St. Jude team modified the therapy by combining this molecule with topotecan, a drug also being investigated in the therapy of retinoblastoma. Local delivery of this two-drug targeted therapy was even more effective, reducing tumor size significantly more than the most effective known combination of standard chemotherapy drugs.

"The findings suggest that this therapy not only could offer children with retinoblastoma more effective and less-toxic therapy," Dyer said. "It could also increase the chance that their vision can be preserved by eliminating the tumor and preventing its spread from the eye to the rest of the body."

The discovery that blocking MDMX releases the apoptosis response in retinoblastoma has important implications for certain forms of adult cancers as well. "Some forms of breast, lung, prostate and colon cancer are caused by abnormally large quantities of MDMX in the cells," Dyer explained. "So knocking out MDMX in those cancers might also dramatically reduce tumor size. And administering the drug directly to the site of the tumor could make the therapy particularly effective while avoiding the toxicity caused by systemic exposure." This could mean the eventual elimination of all-body chemotherapy for certain cancers.

This work is likely to have its biggest impact on the care of children with retinoblastoma internationally, as per Dyer. Most children in the United States with retinoblastoma do not die from the disease because they benefit from early detection and advanced medical therapy. The complex therapy includes chemotherapy, radiation and laser treatment, as well as control of infections caused by therapy-related suppression of the immune system. However, most of the 5,000 children worldwide who are found to have retinoblastoma live primarily in countries with limited resources and have restricted access to medical therapy, as per Carlos Rodriguez-Galindo, M.D., an associate member of the St. Jude Oncology department.

"Today, those children do not have access to the advanced therapys available in other countries, such as the United States," Rodriguez-Galindo said, "but our new approach has the potential to make the therapy of retinoblastoma simpler and less toxic. Ideally, these therapys could be administered even in countries that cannot afford the highly complex infrastructure now mandatory to manage children with retinoblastoma. This would mean saving a number of more lives and preserving more vision." Rodriguez-Galindo is a co-author of the paper.

Retinoblastoma can occur as a unilateral (one eye) or bilateral (both eyes) disease. In the case of unilateral disease, surgeons generally remove the eye that has the cancer in order to prevent the disease from spreading. However, children with bilateral retinoblastoma pose a significant challenge to physicians, who are reluctant to remove both eyes from young children, said Matthew Wilson, M.D., a surgeon in the St. Jude ophthalmology division and a co-author of the paper. In those cases, the physicians institute aggressive systemic chemotherapy to reduce the size of the tumor, followed by one of several possible therapies such as radiation or lasers to destroy the remaining cancer cells in the eye. "When successful, this treatment often saves vision," Wilson said. "Clinicians at major medical institutions generally save 70 percent of all eyes treated, even in the case of advanced disease." .


Posted by: Mike    Source




Did you know?
Researchers at St. Jude Children's Research Hospital have demonstrated in a mouse model a new, locally applied therapy for the eye cancer retinoblastoma that not only greatly reduces the size of the tumor, but does so without causing the side effects common with standard chemotherapy. The therapy also appears to be suitable for certain forms of breast, lung, prostate and colon cancer, and is simple enough for widespread use even in countries with limited resources.

Medicineworld.org: Breakthrough In Eye Cancer Treatment

Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news| Pancreatic cancer news| Prostate cancer news| Endometrial cancer news| General info| What is cancer?| Cancer causes| Is cancer hereditary?| Types of cancer| Cancer statistics| Breast cancer main| Breast cancer symptoms| Colon cancer main| Anal cancer| Bladder cancer main| Lung cancer general| Lung cancer main| Non small cell| Small cell| Ovarian cancer main| Treatment of ovarian cancer| Prostate cancer main| Updates in oncology| Acute myeloid leukemia|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.